论文部分内容阅读
目的:探讨进展期胃癌采用新辅助化疗的临床疗效,以作参考指导临床治疗及预后。方法:选取我院2012年1月至2013年1月肿瘤科收治的60例进展期胃癌患者作为研究对象,其中30例患者进行常规手术,为对照组;30例患者采用新辅助化疗+手术治疗,为治疗组,治疗组患者需化疗时长为2个周期,化疗结束后进行CT复查,后继续实施手术治疗。结果:治疗组的临床疗效显著比对照组好,2组患者的肿瘤切除率、根治性切除率和剖腹探查率、术后生存期均具有显著统计学差异(P<0.05)。2组患者都没有出现死亡案例,发生并发症的几率没有显著统计学差异。结论:进展期胃癌采用新辅助化疗可以显著延长患者的术后生存期,尤其对于手术切除困难、难以根治的局部晚期胃癌患者来说十分必要,可以明显提高临床疗效,改善患者生存质量。
Objective: To investigate the clinical effect of neoadjuvant chemotherapy in advanced gastric cancer and to guide the clinical treatment and prognosis. Methods: Sixty patients with advanced gastric cancer who were admitted to Department of Oncology from January 2012 to January 2013 in our hospital were selected as the research object. Thirty patients underwent routine surgery as the control group. Thirty patients underwent neoadjuvant chemotherapy plus surgery , For the treatment group, the treatment group patients required chemotherapy for a period of 2 cycles after the end of chemotherapy CT review, and then continue to implement the surgical treatment. Results: The clinical efficacy of the treatment group was significantly better than that of the control group. The tumor resection rate, radical resection rate, laparotomy rate and postoperative survival time of the two groups were significantly different (P <0.05). No deaths occurred in either group, and there was no statistically significant difference in the probability of complications. Conclusion: Neoadjuvant chemotherapy can significantly prolong the postoperative survival time of patients with advanced gastric cancer, especially for patients with locally advanced gastric cancer who have difficulty in resection and are difficult to cure. It can significantly improve the clinical efficacy and improve the quality of life of patients.